Ttk in diagnosis and as a therapeutic target in cancer
CA 2438092 C · Owner: Chiron Corporation · Inventors: Jefferson, Anne B.; Reinhard, Christoph; Chan, Vivien W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK as well as diagnostic, prognostic , and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy e.g. as the basis of , rational therapy. In addition the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 21, 2002 and granted August 9, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 21, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 21, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.